LWANC
TGTX icon

Laurel Wealth Advisors (North Carolina)’s TG Therapeutics TGTX Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-315
Closed -$12K – 740
2021
Q2 		$12K Buy
+315
New +$12.4K ﹤0.01% 447

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s TGTX Position: Q3 2021 in Review

Laurel Wealth Advisors (North Carolina) sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 315 shares — an estimated $12K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in TGTX in Q2 2021 and held it in 1 quarter. The position peaked at $12K in Q2 2021. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Laurel Wealth Advisors (North Carolina) reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 315 TG Therapeutics shares in Q3 2021, an estimated $12K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in TG Therapeutics in Q2 2021 and held it in 1 quarter.
  • Laurel Wealth Advisors (North Carolina)'s TG Therapeutics position peaked at $12K in Q2 2021.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2021, filed 12 Nov 2021.